Draft:Health Systems Innovation Lab

Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page.

Draft:Health Systems Innovation Lab
  • Comment: This reads like an advert and seems to have been written by AI / LLM. It's not permitted to have direct links inside the article. Citebombs, WP:CITEBOMB are unhelpful to the reader. Language is promotional. Sources barely mention the laboratory, they refer to work done by the lab. This is not a summary of reliable sources. ChrysGalley (talk) 19:33, 23 February 2026 (UTC)

Health Systems Innovation Lab
Established2021; 5 years ago (2021)
Research typeBasic and translational research and innovation and venture research
Field of research
Health system dynamics, Health system performance, Complex adaptive systems, Health policy, Innovation adoption and diffusion, Entrepreneurship, Medicine
DirectorRifat Atun
LocationBoston, United States
AffiliationsHarvard T.H. Chan School of Public Health
Harvard University
Websitehttps://hsph.harvard.edu/research/health-systems-innovation-lab/

Health Systems Innovation Lab (HSIL) is a global research and training lab based at the Harvard T.H. Chan School of Public Health. It focuses on health system performance, health policy, and venture creation, and conducts its work across two interrelated streams—health systems and innovation—through a Harvard-based interdisciplinary team and an international collaborative network.

HSIL is internationally known for convening the world's largest health systems innovation event, the Annual Health Systems Innovation Hackathon,[1][2][3] which has generated a global venture pipeline dedicated to healthcare innovation and health system transformation, engaging more than 6,000 participants across 40 hubs in over 30 countries and incubating more than 100 ventures.

History and purpose

The lab was established under the leadership of Rifat Atun, Professor of Global Health Systems at Harvard University, Vice-Dean for Innovation and Non-Degree Education at the Harvard T.H. Chan School of Public Health.[4] He has been listed by Clarivate as a Highly Cited Researcher.[5][6] HSIL undertakes research, education, innovation, and translation activities to engage innovators, researchers, practitioners, and collaborators from government, the private sector, multilateral entities, and civil society to support high-value health systems and accelerate the diffusion of healthcare innovations.[7][8][9] Since 2021, HSIL has expanded into a global network of academic, policy, and industry partners spanning more than 60 countries.

Research and initiatives

HSIL’s work spans research, education, and translation activities:

  • Research – assessing health system performance, informing the implementation of health system innovations, and evaluating their impact to support progress toward high-value health systems. Risk Factors (e.g., Hypertension, Hypercholsterolemia) Diseases (e.g., Cancer, Cardiovascular Disease), Treatment Modalities (e.g., Surigery, Radiotherapy), Governance and Organization (e.g., National Cancer Control Plans), Financing (e.g., Innovative Financing and Fiscal Space), and Resource Management (e.g., Artificial Intelligence, Infrastrucure), among others, have been used as 'tracers' to analyse and measure system performance using an HSIL health systems analysis proprietary framework.[10][11][12][13][14][15][16][17][18][19]
  • Education – training students, researchers, policymakers, and practitioners to design, implement, and scale innovations to improve health system performance.[20][21][22]
  • Translation – translating research findings into policy and practice through support for innovation ecosystems, venture incubation, and advisory work with public and private entities.[23][24][25]

Flagship programs and projects

HSIL’s flagship programs and projects include:

Global collaboration and impact

HSIL researchers have produced more than 250 peer-reviewed publications, including work in The Lancet Oncology, The Lancet Global Health, BMJ Global Health, Nature Medicine, and The Lancet Digital Health.

HSIL coordinates a network of more than 40 hubs in over 30 countries, bringing together universities, ministries of health, civil-society organizations, and industry partners, including Microsoft, Novo Nordisk, Roche, Movement Health Foundation, and PATH.

HSIL convenes policy workshops and participates in international forums including the World Health Assembly, World Health Summit, World Economic Forum, the International Society for Pediatric and Adolescent Diabetes, and Lancet Commission meetings.[50]

More than 2,200 students and professionals have been trained through HSIL-affiliated courses and initiatives.

The lab has produced more than 25 policy reports and several global case studies to support reforms and venture-building activities in multiple countries.

Leadership and team

HSIL comprises an interdisciplinary team including clinicians, data scientists, economists, engineers, epidemiologists, public health experts, policy specialists, and computer scientists.

  • Rifat Atun — Director
  • Che L. Reddy — Associate Director, Innovation and Translation
  • Zach Ward — Associate Director, Research
  • Brooke Forde — Project Coordinator and Communications Lead
  • Maia Cullen — Project Coordinator
  • Trishan Panch — Lead, Digital Health
  • Salim Afshar — Lead, AI Translation; Assistant Professor, Harvard School of Dental Medicine; Digital Health Accelerator, Boston Children’s Hospital
  • Jake Figi — Postdoctoral Research Fellow; Lead GC-CDIC
  • Dorit Talia Stein — Co-Lead, Health Systems Performance Analysis and Readiness Assessment
  • Caleb Kumar — Research Assistant, Lead AI for Policy Analysis
  • Karima Ladhani — Visiting Scientist, ARLP
  • Hugh Pearson — Focal Person, GHPL
  • Alem Aminu Osman — Lead, HSIL Annual Hackathon and Visualizer
  • Rodger LeGrand — Learning Design Specialist
  • William Wang — Learning Design Specialist
  1. ^ By (2024-04-16). "Hackathon sparks digital, AI solutions to improve health care | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  2. ^ By (2025-07-23). "Startups vie for investor funding in Health Systems Innovation Lab competition | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  3. ^ By (2023-04-27). "Hackathon seeks digital solutions to health system challenges in Latin America, Caribbean | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  4. ^ By (2025-09-12). "Expanding lifelong learning opportunities at Harvard Chan School | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  5. ^ By (2025-12-18). "Harvard Chan School researchers among world's most highly cited | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  6. ^ "Clarivate Highly Cited Researchers 2025". 2025-10-07. Retrieved 2026-01-08.
  7. ^ "Novartis, Novo Nordisk and Health Systems Innovation Lab at Harvard University partner to transform cardiovascular health".
  8. ^ "Innovative approaches to securing a healthy Commonwealth spotlighted in meetings". Commonwealth. Retrieved 2026-01-08.
  9. ^ "Strategic Public-Private Partnerships to Transform Cardiovascular Health" (PDF).
  10. ^ Nepogodiev, Dmitri; Picciochi, Maria; Ademuyiwa, Adesoji; Adisa, Adewale; Agbeko, Anita E.; Aguilera, Maria-Lorena; Agyei, Fareeda; Alexander, Philip; Henry, Jaymie; Anyomih, Theophilus T. K.; Aregawi, Alazar B.; Atun, Rifat; Biccard, Bruce; Chalwe, Mumba; Chu, Kathryn (2025-08-23). "Surgical health policy 2025-35: strengthening essential services for tomorrow's needs". Lancet. 406 (10505): 860–880. doi:10.1016/S0140-6736(25)00985-7. ISSN 1474-547X. PMID 40675172.
  11. ^ "The State of Cardiovascular Disease in G20+ Countries" (PDF).
  12. ^ Atun, Rifat; Bhakta, Nickhill; Denburg, Avram; Frazier, A. Lindsay; Friedrich, Paola; Gupta, Sumit; Lam, Catherine G.; Ward, Zachary J.; Yeh, Jennifer M.; Allemani, Claudia; Coleman, Michel P.; Di Carlo, Veronica; Loucaides, Eva; Fitchett, Elizabeth; Girardi, Fabio (April 2020). "Sustainable care for children with cancer: a Lancet Oncology Commission". The Lancet. Oncology. 21 (4): e185–e224. doi:10.1016/S1470-2045(20)30022-X. hdl:10072/395643. ISSN 1474-5488. PMID 32240612.
  13. ^ Stein, Dorit Talia; Reitsma, Marissa B.; Geldsetzer, Pascal; Agoudavi, Kokou; Aryal, Krishna Kumar; Bahendeka, Silver; Brant, Luisa C. C.; Farzadfar, Farshad; Gurung, Mongal Singh; Guwatudde, David; Houehanou, Yessito Corine Nadège; Malta, Deborah Carvalho; Martins, João Soares; Saeedi Moghaddam, Sahar; Mwangi, Kibachio Joseph (February 2024). "Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries". Nature Medicine. 30 (2): 414–423. doi:10.1038/s41591-023-02769-8. ISSN 1546-170X. PMID 38278990.
  14. ^ Atun, Rifat; Jaffray, David A.; Barton, Michael B.; Bray, Freddie; Baumann, Michael; Vikram, Bhadrasain; Hanna, Timothy P.; Knaul, Felicia M.; Lievens, Yolande; Lui, Tracey Y. M.; Milosevic, Michael; O'Sullivan, Brian; Rodin, Danielle L.; Rosenblatt, Eduardo; Van Dyk, Jacob (September 2015). "Expanding global access to radiotherapy". The Lancet. Oncology. 16 (10): 1153–1186. doi:10.1016/S1470-2045(15)00222-3. ISSN 1474-5488. PMID 26419354.
  15. ^ Atun, Rifat; Knaul, Felicia Marie; Akachi, Yoko; Frenk, Julio (2012-12-08). "Innovative financing for health: what is truly innovative?". Lancet. 380 (9858): 2044–2049. doi:10.1016/S0140-6736(12)61460-3. ISSN 1474-547X. PMID 23102585.
  16. ^ Atun, Rifat; Silva, Sachin; Knaul, Felicia M. (July 2017). "Innovative financing instruments for global health 2002-15: a systematic analysis". The Lancet. Global Health. 5 (7): e720–e726. doi:10.1016/S2214-109X(17)30198-5. ISSN 2214-109X. PMID 28619230.
  17. ^ Reddy, Ché L.; Peters, Alexander W.; Jumbam, Desmond Tanko; Caddell, Luke; Alkire, Blake C.; Meara, John G.; Atun, Rifat (June 2020). "Innovative financing to fund surgical systems and expand surgical care in low-income and middle-income countries". BMJ Global Health. 5 (6) e002375. doi:10.1136/bmjgh-2020-002375. ISSN 2059-7908. PMC 7299051. PMID 32546586.
  18. ^ Abdel-Wahab, May; Giammarile, Francesco; Carrara, Mauro; Paez, Diana; Hricak, Hedvig; Ayati, Nayyereh; Li, Jing Jing; Mueller, Malina; Aggarwal, Ajay; Al-Ibraheem, Akram; Alkhatib, Sondos; Atun, Rifat; Bello, Abubakar; Berger, Daniel; Delgado Bolton, Roberto C. (November 2024). "Radiotherapy and theranostics: a Lancet Oncology Commission" (PDF). The Lancet. Oncology. 25 (11): e545–e580. doi:10.1016/S1470-2045(24)00407-8. hdl:2263/98957. ISSN 1474-5488. PMID 39362232.
  19. ^ Ward, Zachary J.; Dupuis, Roxanne; Long, Michael W.; Gortmaker, Steven L. (November 2024). "Association of continuous BMI with health-related quality of life in the United States by age and sex". Obesity. 32 (11): 2198–2206. doi:10.1002/oby.24141. ISSN 1930-739X. PMC 11537809. PMID 39370765.
  20. ^ By (2025-11-13). "Global Health Leadership Program equips professionals with tools to drive change | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  21. ^ By (2025-09-12). "Expanding lifelong learning opportunities at Harvard Chan School | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  22. ^ By (2024-09-12). "Nurturing student entrepreneurs | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  23. ^ "Foundation aims to level health access with digital tech". pharmaphorum. 2023-05-22. Retrieved 2026-01-08.
  24. ^ Hoffman, Maayan (2023-06-03). "New 'Lab' Aims To Leverage Digital Tools For Health Policy Making - Health Policy Watch". Retrieved 2026-01-08.
  25. ^ By (2025-02-07). "Expert panel calls for digital health competencies in medical education | Harvard T.H. Chan School of Public Health". Retrieved 2026-01-08.
  26. ^ "A Strategy for Innovation to Transition to High-Value Health Systems". impact.economist.com. Retrieved 2026-01-08.
  27. ^ Douglas, Ayooluwa O.; Senkaiahliyan, Senthujan; Bulstra, Caroline A.; Mita, Carol; Reddy, Che L.; Atun, Rifat (2025-05-02). "Global Adoption of Value-Based Health Care Initiatives Within Health Systems: A Scoping Review". JAMA Health Forum. 6 (5): e250746. doi:10.1001/jamahealthforum.2025.0746. ISSN 2689-0186. PMC 12084849. PMID 40377931.
  28. ^ "Transitioning to High Value Health Systems -- Report 1 (2023)" (PDF).
  29. ^ "Transitioning to High Value Health Systems -- Report 2 (2024)" (PDF).
  30. ^ "Target Population Outputs (TPOs): Creating High-Value Health Systems Through Strategic Public-Private Partnerships" (PDF).
  31. ^ Ward, Zachary J.; Yeh, Jennifer M.; Reddy, Che L.; Gomber, Apoorva; Ross, Carlo; Rittiphairoj, Thanitsara; Manne-Goehler, Jennifer; Abdalla, Asmahan T.; Abdullah, Mohamed Ahmed; Ahmed, Abdurezak; Ankotche, Amos; Azad, Kishwar; Bahendeka, Silver; Baldé, Naby; Jain, Sunil M. (December 2022). "Estimating the total incidence of type 1 diabetes in children and adolescents aged 0-19 years from 1990 to 2050: a global simulation-based analysis". The Lancet. Diabetes & Endocrinology. 10 (12): 848–858. doi:10.1016/S2213-8587(22)00276-5. ISSN 2213-8595. PMID 36372070.
  32. ^ Gomber, Apoorva; Ward, Zachary J.; Ross, Carlo; Owais, Maira; Mita, Carol; Yeh, Jennifer M.; Reddy, Ché L.; Atun, Rifat (2022). "Variation in the incidence of type 1 diabetes mellitus in children and adolescents by world region and country income group: A scoping review". PLOS Global Public Health. 2 (11) e0001099. doi:10.1371/journal.pgph.0001099. ISSN 2767-3375. PMC 10021400. PMID 36962669.
  33. ^ Ross, Carlo; Ward, Zachary J.; Gomber, Apoorva; Owais, Maira; Yeh, Jennifer M.; Reddy, Ché-L.; Atun, Rifat (2022). "The Prevalence of Islet Autoantibodies in Children and Adolescents With Type 1 Diabetes Mellitus: A Global Scoping Review". Frontiers in Endocrinology. 13 815703. doi:10.3389/fendo.2022.815703. ISSN 1664-2392. PMC 8851309. PMID 35185797.
  34. ^ Rittiphairoj, Thanitsara; Owais, Maira; Ward, Zachary J.; Reddy, Ché L.; Yeh, Jennifer M.; Atun, Rifat (April 2022). "Incidence and prevalence of type 1 diabetes and diabetic ketoacidosis in children and adolescents (0-19 years) in Thailand (2015-2020): A nationwide population-based study". The Lancet Regional Health. Western Pacific. 21 100392. doi:10.1016/j.lanwpc.2022.100392. ISSN 2666-6065. PMC 8829760. PMID 35169761.
  35. ^ "Changing Diabetes® in Children Programme Review" (PDF).
  36. ^ Atun, Rifat; Sirohi, Bhawna; Reddy, Che; Gospodarowicz, Mary (November 2024). "Cancer control in the Commonwealth: a roadmap". The Lancet. Oncology. 25 (11): 1409–1412. doi:10.1016/S1470-2045(24)00591-6. ISSN 1474-5488. PMID 39427670.
  37. ^ Ward, Zachary J.; Gaba, Qassi; Atun, Rifat (September 2024). "Cancer incidence and survival for 11 cancers in the Commonwealth: a simulation-based modelling study". The Lancet. Oncology. 25 (9): 1127–1134. doi:10.1016/S1470-2045(24)00336-X. ISSN 1474-5488. PMID 39127064.
  38. ^ Reddy, Che L.; Sousa, Cecilia; Atun, Rifat (July 2025). "Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study". The Lancet. Oncology. 26 (7): 924–935. doi:10.1016/S1470-2045(25)00168-8. ISSN 1474-5488. PMID 40480237.
  39. ^ Thibodeau, Stephane; Yan, Michael; Sirohi, Bhawna; Atun, Rifat; Moraes, Fabio Ynoe (2025-06-01). "Impact of suboptimal cancer care in the Commonwealth: a scoping review and call to action". The Lancet Oncology. 26 (6): e311–e319. doi:10.1016/S1470-2045(25)00026-9. ISSN 1470-2045. PMID 40449505.
  40. ^ Du, Anbang; Brede, Markus; McIntosh, Stuart A.; Zhang, Beining; Alem, Aminu O.; Borin, Gabriela; Cheah, Wilson; Copson, Ellen; Cutress, Ramsey I.; Folz, Anna; Helms, Emily T.; Memon, Zain; Olaniran, Olabiyi H.; Savva, Constantinos; Thomas, Edward (September 2025). "Public and philanthropic research funding, publications, and research networks for cancer in the Commonwealth and globally between 2016 and 2023: a comparative analysis". The Lancet. Oncology. 26 (9): e466–e476. doi:10.1016/S1470-2045(25)00338-9. ISSN 1474-5488. PMID 40907525.
  41. ^ Atun, Rifat; Fries, Jan Ludwig; Hernandez-Villafuerte, Karla; Müller, Malina; Ostwald, Dennis; Schmitt, Maike (April 2025). "Contribution of investment in health and cancer control to economic growth in Commonwealth countries". eClinicalMedicine. 82 103180. doi:10.1016/j.eclinm.2025.103180. ISSN 2589-5370. PMC 12005225. PMID 40247888.
  42. ^ Lee, John Tayu; Li, Vincent Cheng-Sheng; Wu, Jia-Jyun; Chen, Hsiao-Hui; Su, Sophia Sin-Yu; Chang, Brian Pin-Hsuan; Lai, Richard Lee; Liu, Chi-Hung; Chen, Chung-Ting; Tanapima, Valis; Shen, Toby Kai-Bo; Atun, Rifat (2025-07-29). "Evaluation of performance of generative large language models for stroke care". npj Digital Medicine. 8 (1): 481. doi:10.1038/s41746-025-01830-9. ISSN 2398-6352. PMC 12307639. PMID 40730644.
  43. ^ Panch, Trishan; Szolovits, Peter; Atun, Rifat (December 2018). "Artificial intelligence, machine learning and health systems". Journal of Global Health. 8 (2) 020303. doi:10.7189/jogh.08.020303. ISSN 2047-2986. PMC 6199467. PMID 30405904.
  44. ^ Panch, Trishan; Mattie, Heather; Atun, Rifat (December 2019). "Artificial intelligence and algorithmic bias: implications for health systems". Journal of Global Health. 9 (2): 010318. doi:10.7189/jogh.09.020318. ISSN 2047-2986. PMC 6875681. PMID 31788229.
  45. ^ "Addressing the rising burden of cancer in Argentina: Challenges & opportunities".
  46. ^ "Addressing the rising burden of cancer in Colombia: Challenges & Opportunities".
  47. ^ "Addressing the rising burden of cancer in Chile: Challenges & opportunities".
  48. ^ "Addressing the rising burden of cancer in Brazil: Challenges & opportunities".
  49. ^ "Addressing the Rising Burden of Cancer in Brazil: Challenges & Opportunities -- An Updated Analysis of Brazil's Health System and Cancer Control Policies" (PDF).
  50. ^ "Game-changing roadmap to prevent and control cancer across Commonwealth". Commonwealth. Retrieved 2026-01-08.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.